Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PRION DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PRION DISEASE TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PRION DISEASE TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
6 EPIDEMIOLOGY
6.1 INCIDENCES & PREVELENCE OF CREUTZFELDT-JAKOB DISEASE [CJD] , BY COUNTRY
6.2 INCIDENCES & PREVELENCE OF SPORADIC FATAL INSOMNIA, BY COUNTRY
6.3 INCIDENCES & PREVELENCE OF VARIABLY PROTEASE-SENSITIVE PRIONOPATHY, BY COUNTRY
6.4 INCIDENCES & PREVELENCE OF GENETIC CJD, BY COUNTRY
6.5 INCIDENCES & PREVELENCE OF FATAL FAMILIAL INSOMNIA, BY COUNTRY
6.6 INCIDENCES & PREVELENCE OF GERSTMANN-STRAUSSLER-SCHEINKER SYNDROME, BY COUNTRY
6.7 INCIDENCES & PREVELENCE OF KURU, BY COUNTRY
6.8 INCIDENCES & PREVELENCE OF VARIANT CJD, BY COUNTRY
6.9 INCIDENCES & PREVELENCE OF IATROGENIC CJD, BY COUNTRY
7 INDUSTRY INSIGHTS
8 REGULATORY FRAMEWORK
9 PIPELINE ANALYSIS
9.1 OVERVIEW
9.2 PHASE III CANDIDATES
9.3 PHASE II CANDIDATES
9.4 PHASE I CANDIDATES
9.5 OTHERS
10 GLOBAL PRION DISEASE TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 THE CENTRAL NERVOUS SYSTEM DRUGS
10.2.1 ANTIEPILEPTIC DRUGS
10.2.1.1. CHLORPROMAZINE
10.2.1.2. TOPIRAMATE
10.2.1.3. PHENYTOIN
10.2.1.4. LEVETIRACETAM
10.2.1.5. OTHERS
10.2.2 ANTIDEPRESSANTS AGENTS
10.2.2.1. CLOMIPRAMINE
10.2.2.2. DESIPRAMINE
10.2.2.3. VENLAFAXINE
10.2.2.4. TRIMIPRAMINE
10.2.2.5. OTHERS
10.2.3 OTHERS
10.3 ANTIVIRALS
10.3.1 ACYCLOVIR
10.3.2 AMANTADINE
10.3.3 INTERFERON
10.3.4 VIDARABINE
10.3.5 OTHERS
10.4 ANTIBIOTIC
10.4.1 DOXYCYCLINE
10.4.2 AMPHOTERICIN B
10.4.3 OTHERS
10.5 FLUPIRTINE
10.6 FLUPHENAZINE
10.7 QUINACRINE
10.8 PENTOSAN POLYSULFATE
10.9 OTHERS
11 GLOBAL PRION DISEASE TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 SPORADIC
11.2.1 CREUTZFELDT-JAKOB DISEASE [CJD]
11.2.2 SPORADIC FATAL INSOMNIA
11.2.3 VARIABLY PROTEASE-SENSITIVE PRIONOPATHY
11.3 GENETIC
11.3.1 GENETIC CJD
11.3.2 FATAL FAMILIAL INSOMNIA
11.3.3 GERSTMANN-STRAUSSLER-SCHEINKER SYNDROME
11.4 ACQUIRED
11.4.1 KURU
11.4.2 VARIANT CJD
11.4.3 IATROGENIC CJD
12 GLOBAL PRION DISEASE TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 ELMIRON
12.2.2 ANAFRANIL
12.2.3 NORPRAMIN
12.2.4 EFFEXOR
12.2.5 EPRONTIA
12.2.6 QSYMIA
12.2.7 ABELCET
12.2.8 AMBISOME
12.2.9 OTHER
12.3 GENERICS
13 GLOBAL PRION DISEASE TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 PADEATRICS
13.3 ADULTS
13.4 GERIATRICS
14 GLOBAL PRION DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS
14.2.2 CAPSULE
14.3 INJECTABLES
14.3.1 INTRAMASCULAR
14.3.2 INTRAVENOUS
14.4 OTHERS
15 GLOBAL PRION DISEASE TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 HOMECARE
15.4 SPECIALTY CLINICS
15.5 OTHERS.
16 GLOBAL PRION DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 ONLINE RETAIL CHANNELS
16.3.2 PHARMACY STORES
16.3.3 OTHERS
16.4 OTHERS
17 GLOBAL PRION DISEASE TREATMENT MARKET, BY GEOGRAPHY
GLOBAL PRION DISEASE TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.1.1 NORTH AMERICA
17.1.1.1. U.S.
17.1.1.2. CANADA
17.1.1.3. MEXICO
17.1.2 EUROPE
17.1.2.1. GERMANY
17.1.2.2. U.K.
17.1.2.3. ITALY
17.1.2.4. FRANCE
17.1.2.5. SPAIN
17.1.2.6. RUSSIA
17.1.2.7. SWITZERLAND
17.1.2.8. TURKEY
17.1.2.9. BELGIUM
17.1.2.10. NETHERLANDS
17.1.2.11. DENMARK
17.1.2.12. SWEDEN
17.1.2.13. POLAND
17.1.2.14. NORWAY
17.1.2.15. FINLAND
17.1.2.16. REST OF EUROPE
17.1.3 ASIA-PACIFIC
17.1.3.1. JAPAN
17.1.3.2. CHINA
17.1.3.3. SOUTH KOREA
17.1.3.4. INDIA
17.1.3.5. SINGAPORE
17.1.3.6. THAILAND
17.1.3.7. INDONESIA
17.1.3.8. MALAYSIA
17.1.3.9. PHILIPPINES
17.1.3.10. AUSTRALIA
17.1.3.11. NEW ZEALAND
17.1.3.12. VIETNAM
17.1.3.13. TAIWAN
17.1.3.14. REST OF ASIA-PACIFIC
17.1.4 SOUTH AMERICA
17.1.4.1. BRAZIL
17.1.4.2. ARGENTINA
17.1.4.3. REST OF SOUTH AMERICA
17.1.5 MIDDLE EAST AND AFRICA
17.1.5.1. SOUTH AFRICA
17.1.5.2. EGYPT
17.1.5.3. BAHRAIN
17.1.5.4. UNITED ARAB EMIRATES
17.1.5.5. KUWAIT
17.1.5.6. OMAN
17.1.5.7. QATAR
17.1.5.8. SAUDI ARABIA
17.1.5.9. REST OF MEA SOUTH AFRICA
18 GLOBAL PRION DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL PRION DISEASE TREATMENT MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL PRION DISEASE TREATMENT MARKET, COMPANY PROFILE
20.1 TEVA PHARMACEUTICAL INDUSTRIES LTD
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 DR. REDDY’S LABORATORIES LTD.
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 PFIZER INC
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 SANDOZ INTERNATIONAL GMBH
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 APOTEX INC.
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENTS
20.7 ZYDUS PHARMACEUTICALS INC
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENTS
20.8 GLENMARK PHARMACEUTICALS
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 LANNETT
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.1 CIPLA INC
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 LUPIN
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPMENTS
20.12 ALEMBIC PHARMECAUTICALS
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPMENTS
20.13 APOTEX INC
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPMENTS
20.14 ACCORD HEALTHCARE INC
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENTS
20.15 AURBINDO PHARMA LIMITED
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPMENTS
20.16 LEADIANT BIOSCIENCES, INC.
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 ASTELLAS PHARMA US, INC
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENTS
20.18 JANSSEN PHARMACEUTICALS, INC.
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPMENTS
20.19 FRESENIUN SE & CO
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPMENTS
20.2 NOVARTIS AG
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPMENTS
20.21 MERCK KGAA
20.21.1 COMPANY OVERVIEW
20.21.2 REVENUE ANALYSIS
20.21.3 GEOGRAPHIC PRESENCE
20.21.4 PRODUCT PORTFOLIO
20.21.5 RECENT DEVELOPMENTS
20.22 ASTRA ZENECA
20.22.1 COMPANY OVERVIEW
20.22.2 REVENUE ANALYSIS
20.22.3 GEOGRAPHIC PRESENCE
20.22.4 PRODUCT PORTFOLIO
20.22.5 RECENT DEVELOPMENTS
20.23 BRISTOL – AYERS QUIBB COMPANY
20.23.1 COMPANY OVERVIEW
20.23.2 REVENUE ANALYSIS
20.23.3 GEOGRAPHIC PRESENCE
20.23.4 PRODUCT PORTFOLIO
20.23.5 RECENT DEVELOPMENTS
20.24 ABBOTT
20.24.1 COMPANY OVERVIEW
20.24.2 REVENUE ANALYSIS
20.24.3 GEOGRAPHIC PRESENCE
20.24.4 PRODUCT PORTFOLIO
20.24.5 RECENT DEVELOPMENTS
20.25 STELLA PHARMACEUTICAL CANADA INC.
20.25.1 COMPANY OVERVIEW
20.25.2 REVENUE ANALYSIS
20.25.3 GEOGRAPHIC PRESENCE
20.25.4 PRODUCT PORTFOLIO
20.25.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
